Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion. This story matters for Finance & Markets readers tracking trade. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. Trade-News curates and briefs the finance & markets stories that matter. Our editorial policy →